Prognostic factors of response to adjuvant chemotherapy after curative resection for pancreatic ductal adenocarcinoma: Prognostic impact of CDA, predictive value of DPD for 5FU efficiency, and hENT1 for gemcitabine.

e15191 Background: Since 2005, adjuvant chemotherapy with gemcitabine (Gem) or 5fluorouracil (5FU) plus folinic acid for 6 months is a standard in resected pancreatic cancer. Predictive factors of efficiency of these 2 schemes seems necessary to offer patients a treatment card. This retrospective study evaluated the prognostic value of 7 histological markers (DPD, TS, CDA, hENT1, hCNT3, S100A2, and SMAD 4), and their impact on the efficacy chemotherapy with Gem or 5FU. Methods: From 230 pancreatic resections for cancer, we retrospectively included 193 patients with pancreatic surgery for pancreatic adenocarcinoma (PAC) between March 2005 and December 2012 in three hospitals in Marseille. A TMA (Tissue Micro Array) was constructed using tissue core samples from these tumors. Of these, 63 patients were excluded from the analysis: 9 early postoperative deaths, 7 metastatic disease or R2 resection, 6 received neo-adjuvant treatment, 14 lost of follow up, 27 not included in the TMA. Finally, 123 patients were ...